Ocular Therapeutix Inc - ESG Rating & Company Profile powered by AI
The ESG rating covers 17 United Nations SDGs including: 'Clean Water & Sanitation', 'Responsible Production & Consumption' and 'Partnerships for the Goals'. The webpage contains a Q&A table about Ocular Therapeutix Inc. Detailed Sustainability analysis of Ocular Therapeutix Inc can be reached by signing in.
Ocular Therapeutix Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.5; made up of an environmental score of 2.7, social score of 2.3 and governance score of 2.0.
2.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 1954 | Vaxcell Bio Therapeutics | 2.6 | Medium |
| 1954 | Zhejiang Starry Pharmaceutical Co Ltd | 2.6 | Medium |
| 1976 | Ocular Therapeutix Inc | 2.5 | Medium |
| 1976 | Chemon Inc | 2.5 | Medium |
| 1976 | Chengdu Kanghong Pharmaceutical Group Co Ltd | 2.5 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Ocular Therapeutix Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Ocular Therapeutix Inc report the average age of the workforce?
Sign up for free to unlockDoes Ocular Therapeutix Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Ocular Therapeutix Inc offer flexible work?
Sign up for free to unlockDoes Ocular Therapeutix Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Ocular Therapeutix Inc conduct supply chain audits?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Ocular Therapeutix Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose water use targets?
Sign up for free to unlockDoes Ocular Therapeutix Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Ocular Therapeutix Inc have a product recall in the last two years?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Ocular Therapeutix Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Ocular Therapeutix Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose parental leave metrics?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Ocular Therapeutix Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Ocular Therapeutix Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Ocular Therapeutix Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose its waste policy?
Sign up for free to unlockDoes Ocular Therapeutix Inc report according to TCFD requirements?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose energy use targets?
Sign up for free to unlockDoes Ocular Therapeutix Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Ocular Therapeutix Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Ocular Therapeutix Inc
These potential risks are based on the size, segment and geographies of the company.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.